Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22199020 | 0.82 | CYP11B2 (0.43) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL15442444 | 0.81 | NR2E1 (0.49) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL9701793 | 0.80 | NR2E1 (0.48) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL22199045 | 0.79 | USP30 (0.47) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL9699728 | 0.79 | NR2E1 (0.46) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL12676199 | 0.79 | USP30 (0.40) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL1903855 | 0.77 | GRIA1 (0.42) | CYP1A2 | |
| SCHEMBL3343040 | 0.76 | NR2E1 (0.48) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL1824196 | 0.75 | CYP3A4 (0.46) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL15222204 | 0.75 | MAOA (0.50) | NR2E1CYP1A2CYP3A4CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633208-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands | ROTTAPHARM S.P.A (IT) | 2014-01-21 | — | — | US | disclosed |
| US-8633208-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands | ROTTAPHARM S.P.A (IT) | 2014-01-21 | — | — | US | disclosed |
| US-8633208-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands | ROTTAPHARM S.P.A (IT) | 2014-01-21 | — | — | US | disclosed |
| EP-2315588-B1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM SPA (IT) | 2012-12-19 | — | — | EP | disclosed |
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2315588-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | Rottapharm S.p.A. (IT) | 2011-05-04 | — | — | EP | disclosed |
| WO-2009152868-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2009-12-23 | — | — | WO | disclosed |
| EP-0691967-B1 | NITROGEN-CONTAINING FUSED-HETEROCYCLE COMPOUNDS | EISAI CO LTD (JP) | 1998-09-02 | — | — | EP | disclosed |
| US-5707998-A | CYCLIC-GMP PHOSPHODIESTERASE INHIBITORS, TREATING CARDIOVASCULAR DISORDERS AND ASTHMA | EISAI CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | OPRM1, OPRD1, HTR3C | NR2E1 428/4885CYP1A2 46/4885CYP3A4 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.